Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.
These drugs are the GLP1 receptor agonists like Exenatide, Liraglutde, Dulaglutide, Semaglutide and the dual GLP/ GIP Analogue Tirzepatide. Both these drugs are recent innovations that have taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback